Market Activity, Acquisition Closure, App Launch, New Offering, and Exercise of Options - Research Reports on Conn's, Abbott, 3M, Alibaba Group and Banco Bradesco

NEW YORK, October 2, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Conn's Inc. (NASDAQ: CONN), Abbott Laboratories (NYSE: ABT), 3M Company (NYSE: MMM), Alibaba Group Holding Limited (NYSE: BABA) and Banco Bradesco S.A. (NYSE: BBD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6928-100free.

--
Conn's Inc. Research Reports
On September 29, 2014, the stock of Conn's Inc. (Conn's) ended the session at $30.70, up 6.49%. The stock opened the session at $28.73 and oscillated in the range of $28.43-$31.18 with a trading volume of 4.97 million shares. YTD shares in Conn's fell 60.99% as compared to the NASDAQ Composite Index, which gained 8.47% during the same trading period. The stock closed 15.41% above its 52-week low of $26.60. As per the SEC filings made by Luxor Capital Group, LP and associated funds (together, Luxor Capital) on September 26, 2014, September 25, 2014, and September 24, 2014, Luxor Capital has acquired a total of 1,073,414 units of common stock of Conn's for an average price of $27.82 over this time period. The full research reports on Conn's are available to download free of charge at:

http://www.analystsreview.com/Oct-02-2014/CONN/report.pdf

--
Abbott Laboratories Research Reports
On September 26, 2014, Abbott Laboratories (Abbott) reported that it has completed the acquisition of CFR Pharmaceuticals (CFR Pharma), establishing itself among the top 10 pharmaceutical companies in Latin America. According to the Company, Abbott's indirect acquisition of over 99% of CFR Pharma's ordinary shares for c. $2.9 billion has not only resulted in over two-fold growth in its Latin American branded generics pharmaceutical presence, but has also expanded the Company's presence in the fast-growing markets. Miles D. White, Chairman and CEO, Abbott, said, "By adding CFR's portfolio of well-known, trusted products, Abbott has taken another key step in actively shaping its portfolio to better meet the evolving needs of health care and drive sustainable growth." According to the Company, the transaction will not impact Abbott's ongoing earnings-per-share guidance for 2014. However, Abbott anticipates this transaction to be accretive to ongoing earnings per share in 2015. The full research reports on Abbott are available to download free of charge at:

http://www.analystsreview.com/Oct-02-2014/ABT/report.pdf

--
3M Company Research Reports
On September 25, 2014, 3M Company (3M) reported introduction of Post-it Plus App by its Post-it Brand. According to the Company, the new app captures up to 50 Post-it Notes at once from a Post-it Note collaboration session and digitizes them, allowing groups to shorten transcription time, share, organize or refine ideas quickly and add to the discussion from anywhere. Paul Kim, Vice President and General Manager at stationery and office supplies, 3M, said, "Post-it Notes continue to be the go-to tool for capturing thoughts and ideas in the analog world. As technology continues to permeate every aspect of our lives, the ability to instantly capture Post-it Notes with the Post-it Plus App means that collaboration leaders can have the same simple, intuitive Post-it Note experience, and now share those ideas with others in the digital world." The full research reports on 3M are available to download free of charge at:

http://www.analystsreview.com/Oct-02-2014/MMM/report.pdf

--
Alibaba Group Holding Limited Research Reports
On September 22, 2014, Alibaba Group Holding Limited (Alibaba Group) announced that the underwriters of its previously announced initial public offering have fully exercised the option to purchase an additional 48,015,900 American depositary shares (ADSs) from the Company and certain selling shareholders. According to Alibaba Group, post the full exercise of underwriters' option, the Company and the selling shareholders raised gross proceeds of c. $25.03 billion from the initial public offering, which made history as the biggest IPO in the U.S. The full research reports on Alibaba Group are available to download free of charge at:

http://www.analystsreview.com/Oct-02-2014/BABA/report.pdf

--
Banco Bradesco S.A. Research Reports
On September 29, 2014, the stock of Banco Bradesco S.A. (Banco Bradesco) ended the session at $14.55, down 8.38%. The stock opened the session at $14.59 and oscillated in the range of $14.47-$14.96, with a trading volume of 14.16 million shares. Year-to-date, Banco Bradesco stock has gained 17.72% as compared to the NASDAQ Composite Index, which has gained 3.78% during the same trading period. The full research reports on Banco Bradesco are available to download free of charge at:

http://www.analystsreview.com/Oct-02-2014/BBD/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review